Cancer death rate has dropped 25 percent since 1991 peak

A steady decline over more than two decades has resulted in a 25% drop in the overall cancer death rate in the United States. The drop equates to 2.1 million fewer cancer deaths between 1991 and 2014. The news comes from Cancer Statistics 2017, the American Cancer Society’s comprehensive annual report on cancer incidence, mortality, and survival.
It is published in CA: A Cancer Journal for Clinicians and is accompanied by a consumer version of the publication, Cancer Facts and Figures 2017.

Click to view all articles for the EPIC: ONC
Or click to view the full company profile:

Oncimmune awarded Queen’s Award for Enterprise in Innovation 2022

21st April 2022

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has been awarded the Queen’s Award for Enterprise 2022 in the innovation category, endorsing Oncimmune as a leading developer of applied immunodiagnostics for

Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

8th April 2022

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

Oncimmune signs new commercial follow-on contract

7th March 2022

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

Oncimmune signs commercial contract with a top 10 global pharmaceutical company

4th March 2022

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a commercial contract with a new top 10 global pharmaceutical company by revenue, initially focusing on the autoantibody profiling of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Oncimmune signs go-to-market partnership with Synexa Life Sciences

1st March 2022

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

Oncimmune growing pipeline supporting improved performance and realisation of value

28th February 2022

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its unaudited interim results for the six months ended 30 November 2021. Financial highlights · Recognised revenue for the period was £1.43M (H1 2020: £1.83M) was

Oncimmune signs new commercial contract with Verily Life Sciences

28th February 2022

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

Oncimmune Holdings Notice of half year results

25th February 2022

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

Oncimmune Holdings further contract signed with leading, top five global pharmaceutical company

15th February 2022

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has today announced it has signed a further commercial contract under its existing master services agreement with a top five global pharmaceutical company, profiling over 350 chronic idiopathic

Oncimmune publication further validates the ImmunoINSIGHTS Infectious Diseases panel

31st December 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the publication of a paper entitled: “Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection” 1 arising from the research collaboration between Oncimmune and Cedars-Sinai Medical Center

Oncimmune signs further commercial contracts within its ImmunoINSIGHTS pharma services business

21st December 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that the Company has signed further commercial contracts within its ImmunoINSIGHTS pharma services business. MSA and Commercial Contract Signed with Leading Global Pharmaceutical Company Following

Oncimmune Holdings significant Q2 FY2022 sales and expansion of business development team in US and Europe

7th December 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today provided an update on commercial activity within its ImmunoINSIGHTS pharma services business. As we highlighted in the full year results announcement released on 2 November 2021, the

Oncimmune achieves FY2021 revenue of £3.7 million

2nd November 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.

Oncimmune to announce its full year results on Tuesday, 2 November 2021

25th October 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, will be announcing its full year results for the year ended 31 May 2021 on Tuesday, 2 November 2021. Analyst and investor presentations Dr Adam M Hill,

Oncimmune to evaluate the profile of patients using ImmunoINSIGHTS

20th September 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The

Three-year follow-up trial data successfully demonstrates survival benefit of Oncimmune’s Early-CDT lung cancer diagnostic

25th August 2021

Oncimmune Holdings plc (LON:ONC) drew attention to the pre-publication of new research demonstrating how the use of its EarlyCDT-Lung Test, for diagnosing early stage lung cancer, has been shown to reduce mortality when used as part

Oncimmune pre-publication of the three-year follow-up data for the ECLS trial

23rd August 2021

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the pre-publication of the three-year follow-up data for the Early detection of Cancer of the Lung Scotland trial in medRxiv titled ‘Targeted screening for lung

Oncimmune new ImmunoINSIGHTS contract further validates offering and supports expected sales growth

26th July 2021

Oncimmune Holdings plc (LON:ONC) announced a new contract with the Dana-Farber Cancer Institute (Harvard Medical School affiliate based in Boston, US) whereby the latter will utilise Oncimmune’s proprietary SeroTagTM ‘biomarker discover engine’ to identify predictive patient responses

Be sure to check our sister interview main ratings news website